Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Onconova Announces Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
Oral rigosertib progresses to phase 2 clinical trial in squamous cell head and neck cancers.

Onconova Therapeutics, Inc. announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented at the American Association for Cancer Research (AACR) Annual Meeting. The presentation was made by Antonio Jimeno, MD, PhD, of the University of Colorado School of Medicine and Director of the University’s Head and Neck Cancer Medical Oncology Program.

The oral presentation by Dr. Jimeno entitled, “Phase 1 and molecular correlates study of oral rigosertib in patients with refractory metastatic head and neck cancer and advanced solid tumors,” reported on the safety and activity of rigosertib in 48 patients. The objectives of this study were to define dose limiting toxicity, to characterize the pharmacokinetic (PK) profile, and to identify anti-tumor activity. Oral rigosertib was generally well tolerated. Notably, two of the six metastatic head and neck squamous cell carcinoma patients, with disease refractory to previous platinum-based therapy, showed anti-tumor responses. These responses included a confirmed complete response (CR) as well as a confirmed partial response (PR). These patients have received single-agent oral rigosertib for 98 and 48 weeks, respectively.

“The encouraging data reported today at AACR, describing the tolerability and clinical activity of oral rigosertib in advanced head and neck cancer, have driven the initiation of an 80-patient, multi-institutional nationwide Phase 2 trial in this patient population. Additionally, two Phase 2 trials, supported by proof of activity in earlier Phase 1 trials, are currently exploring utility of oral rigosertib in transfusion-dependent lower-risk MDS patients,” commented François Wilhelm, MD, PhD, Chief Medical Officer of Onconova. “We believe that these findings provide clinical support for further investigation of oral rigosertib as a treatment for advanced solid tumors, including metastatic head and neck cancer.”

Rigosertib has been extensively studied in clinical trials conducted in the U.S., Europe, Japan and India, in patients with solid tumors and blood cancers, with more than 850 patients enrolled in Phase 1, 2 and 3 trials, including a pivotal randomized Phase 3 trial conducted under a special protocol assessment (SPA) for patients with higher-risk myelodysplastic syndromes (MDS) previously treated with hypomethylating agents. Rigosertib, a patented new chemical entity, has received orphan designation for MDS and pancreatic cancer.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Cancer Cells Coordinate to Form Roving Clusters
Rice University scientists identify ‘smoking gun’ in metastasis of hybrid cells.
Poliovirus Therapy Wins 'Breakthrough' Status
FDA decision will fast-track research on breakthrough Duke brain cancer therapy.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
New Treatment for Pancreatic Cancer
Researchers at Purdue University have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!